Division of Emergent BioSolutions Inc.
Latest From PaxVax Inc.
US FDA’s Medical Countermeasures Initiative authorities like emergency use authorization have not yet had much of an impact on drugs and biologics, but agency is committed to supporting a swift response to the new strain of coronavirus.
As the mosquito-borne chikungunya virus spreads into temperate regions worldwide, US FDA convenes advisory committee for an open discussion on development of vaccines.
Following its purchase of PaxVax earlier this month, Emergent is taking on Narcan nasal spray for opioid overdose as part of its acquisition of Adapt. Also-busy Evotec teams up with Centogene in rare genetic disease and Novo in diabetes/obesity.
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
- Drug Delivery
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Emergent BioSolutions Inc.
- Senior Management
Nima Farzan, Pres. & CEO
Philip K Moody, EVP, CFO
Jonathan F Smith, PhD, EVP, CSO
Mark Meltz, EVP, CBO
- Contact Info
Phone: (650) 847-1075
555 Twin Dolphin Dr., Ste. 360
Redwood City, CA 94065
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.